Sanofi, Regeneron: Phase 3 Trial for Dupilumab Show Positive Results
June 06 2016 - 2:03AM
Dow Jones News
By Inti Landauro
PARIS-- French drug giant Sanofi (SAN.FR) and U.S. partner
Regeneron Pharmaceuticals (REGN) said a one-year phase three trial
study showed a treatment combining their drug dupilumab with
topical corticosteroids significantly improved the situations of a
group of patients suffering from atopic dermatitis.
The treatment including dupilumab improved the overall severity
of the disease for patients whose atopic dermatitis was
inadequately controlled by a treatment of just topical
corticosteroids, the companies said Monday.
The patients who took the dupilumab treatment were compared with
another group of similar patients who took topical corticosteroids
and a placebo.
Large pharmaceutical labs like Sanofi are rushing to develop new
drugs to replace a number of existing drugs that are entering the
public domain, which would allow generic pharmaceutical groups to
produce and sell the same drugs at a fraction of the current price,
a phenomenon known as the "patent cliff."
-Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
June 06, 2016 01:48 ET (05:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2024 to May 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From May 2023 to May 2024
